S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
MarketsFN
Home/Hedge Funds/Baker Bros Advisors/Q2 2022

Baker Bros Advisors

Period: Q2 2022 Β· Filed: 2022-08-15
View on SEC EDGAR β†—
AUM
$17.63B
Total portfolio value
Positions
117
Reported securities
Top Holding
SGEN
47.1% $8.30B
QoQ Changes
+5 / -6
new Β· exited
⚠️13F Filing Disclosure

AUM figures shown are calculated by summing the reported market value of all positions in SEC 13F-HR filings β€” not the fund's actual assets under management.

  • Excludes cash, bonds, private equity, short positions, and foreign-listed stocks not required to be reported.
  • For PUT and CALL options, the reported Value is the notional value of the underlying shares β€” not the option premium paid. This significantly overstates the actual capital at risk.
  • Actual fund AUM is typically higher and includes strategies, instruments, and positions that never appear in a 13F.
  • 13F filings cover institutional managers with β‰₯$100M in 13F securities. Positions reflect end-of-quarter holdings, disclosed up to 45 days after the period ends.

Data sourced from SEC EDGAR. This tracker is for informational purposes only and does not constitute investment advice.

Portfolio Holdings

Top 30 positions

⚠️ Performance % calculated from filing date ( 2022-08-15) shown is the underlying stock price movement β€” not the derivative's P&L.
TickerIssuerNotionalPort %@ FilingNow (EOD)Since FilingAllocation
SGENSeagen Inc.$8.30B47.09%β€”β€”
47.1%
INCYIncyte Corporation$2.75B15.58%$75.97$116.86+53.8%
15.6%
ONCBeiGene, Ltd.$1.89B10.71%$161.85$297.65+83.9%
10.7%
BMRNBioMarin Pharmaceutical Inc.$631.5M3.58%$82.87$58.99-28.8%
3.6%
ACADACADIA Pharmaceuticals Inc.$590.7M3.35%$14.09$25.97+84.3%
3.4%
ASNDAscendis Pharma A/S$451.1M2.56%$92.96$274.50+195.3%
2.6%
ARGXargenx SE$424.2M2.41%$378.88$939.68+148.0%
2.4%
BCRXBioCryst Pharmaceuticals, Inc.$134.5M0.76%$10.58$9.84-7.0%
0.8%
KODKodiak Sciences Inc.$132.3M0.75%$7.64$38.54+404.4%
0.8%
GBTGlobal Blood Therapeutics, Inc.$119.3M0.68%β€”β€”
0.7%
ABCLAbCellera Biologics Inc.$111.3M0.63%$10.65$8.11-23.9%
0.6%
MDGLMadrigal Pharmaceuticals, Inc.$107.3M0.61%$71.58$528.10+637.8%
0.6%
MRTXMirati Therapeutics, Inc.$94.6M0.54%β€”β€”
0.5%
IMCRImmunocore Holdings plc$94.0M0.53%$37.31$32.50-12.9%
0.5%
HZNPHorizon Therapeutics Public Ltd Co$91.6M0.52%β€”β€”
0.5%
CERSCerus Corporation$85.0M0.48%$5.29$3.16-40.3%
0.5%
TVTXTravere Therapeutics, Inc.$80.0M0.45%$24.23$56.92+134.9%
0.5%
REPLReplimune Group, Inc.$62.8M0.36%$17.48$11.58-33.8%
0.4%
TRDAEntrada Therapeutics, Inc.$59.3M0.34%$12.18$7.72-36.6%
0.3%
IGMSIGM Biosciences, Inc.$56.9M0.32%β€”β€”
0.3%
KYMRKymera Therapeutics, Inc.$56.7M0.32%$19.69$113.51+476.5%
0.3%
KRYSKrystal Biotech, Inc.$53.0M0.30%$65.66$375.07+471.2%
0.3%
PRLDPrelude Therapeutics Inc.$52.9M0.30%$5.22$4.91-5.9%
0.3%
NRIXNurix Therapeutics, Inc.$49.2M0.28%$12.67$23.97+89.2%
0.3%
LEGNLegend Biotech Corporation$47.1M0.27%$55.00$29.91-45.6%
0.3%
ALKSAlkermes plc$44.7M0.25%$29.79$54.58+83.2%
0.3%
CCXIChemoCentryx, Inc.$44.4M0.25%β€”$19.10
0.3%
KDNYChinook Therapeutics, Inc.$44.3M0.25%β€”β€”
0.3%
INSMInsmed Incorporated$42.5M0.24%$19.72$111.60+465.9%
0.2%
IMTXImmatics N.V.$38.5M0.22%$8.71$9.95+14.2%
0.2%

Quarter-on-Quarter Activity

Q2 2022 vs. Q1 2022

New Positions (5)

TickerIssuerNotional
ATRAAtara Biotherapeutics, Inc.$5.8M
VORXXXXVor Biopharma Inc.$5.7M
NKTXNkarta, Inc.$4.9M
NTRANatera, Inc.$3.5M
EVFMEvofem Biosciences, Inc.$2.9M

Exited Positions (6)

TickerIssuerNotional
NBIXNeurocrine Biosciences, Inc.$63.5M
AXSMAxsome Therapeutics, Inc.$25.3M
SRPTSarepta Therapeutics, Inc.$9.6M
KURAKura Oncology, Inc.$4.4M
NVAXNovavax, Inc.$3.5M
OYSTOyster Point Pharma, Inc.$0.7M

Increased (8)

TickerIssuerNotionalShares Ξ”Since Filing
DNLIDenali Therapeutics Inc.$14.5M+563.5%
CYTTCyteir Therapeutics, Inc.$4.8M+225.3%
REPLReplimune Group, Inc.$35.4M+122.8%-33.8%
MGNXMacroGenics, Inc.$-1.3M+101.7%
CCXIChemoCentryx, Inc.$21.4M+95.5%
TCRXTScan Therapeutics, Inc.$4.8M+95.4%
ALTAltimmune, Inc.$17.8M+93.6%
NRIXNurix Therapeutics, Inc.$14.8M+58.2%+89.2%

Trimmed (7)

TickerIssuerNotionalShares Ξ”Since Filing
NEXINexImmune, Inc.$-1.2M-93.2%
NGMNGM Biopharmaceuticals, Inc.$-3.7M-81.1%
LEGNLegend Biotech Corporation$-25.9M-57.4%-45.6%
KZRKezar Life Sciences, Inc.$-1.8M-55.7%
MRUSMerus N.V.$-31.3M-51.1%
ATYRaTyr Pharma, Inc.$-2.3M-40.1%
TCDAQTricida, Inc.$0.3M-13.2%
← Back to Hedge Funds